// App-Quantinova.ai

1433 : A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

Researchers

Presenter

  • Ulf Müller-Ladner

Principal Investigators

  • Karl Gaffney

  • Deepak Jadon

  • Marco Matucci-Cerinic

  • Eugenio Chamizo Carmona

  • Janet Addison

Medical Centers

  • JLU Campus KK, Bad Nauheim, Germany

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • Cambridge University Hospitals, Cambridge, United Kingdom

  • University of Florence, Florence, Italy

  • Hospital de Merida, Merida, Spain

  • Biogen Idec Ltd, Maidenhead, United Kingdom

Locations

  • Philippines

  • Germany

  • United Kingdom

  • Italy

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

  • Gastroenterology (GU)

Disease

  • Axial spondyloarthritis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Ulcerative colitis

  • Spondyloarthritis

  • Crohn's disease

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved